Raras
Buscar doenças, sintomas, genes...
Doença do núcleo central
ORPHA:597CID-10 · G71.2CID-11 · 8C72.02OMIM 117000DOENÇA RARA

Doença congênita autossômica dominante que afeta os músculos esqueléticos. Microscopicamente, é caracterizada por áreas desorganizadas, chamadas núcleos, vistas geralmente no centro das fibras musculares. Clinicamente apresenta-se como fraqueza muscular leve a grave. Pode estar associada a anormalidades esqueléticas, incluindo escoliose, deformidades articulares e luxação do quadril.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença congênita autossômica dominante que afeta os músculos esqueléticos. Microscopicamente, é caracterizada por áreas desorganizadas, chamadas núcleos, vistas geralmente no centro das fibras musculares. Clinicamente apresenta-se como fraqueza muscular leve a grave. Pode estar associada a anormalidades esqueléticas, incluindo escoliose, deformidades articulares e luxação do quadril.

Pesquisas ativas
3 ensaios
5 total registrados no ClinicalTrials.gov
Publicações científicas
472 artigos
Último publicado: 2025 Nov 26

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.4
United Kingdom
Início
Childhood
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G71.2
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
15 sintomas
🦴
Ossos e articulações
4 sintomas
🧠
Neurológico
2 sintomas
😀
Face
2 sintomas
❤️
Coração
1 sintomas
🫁
Pulmão
1 sintomas

+ 16 sintomas em outras categorias

Características mais comuns

100%prev.
Regiões de núcleo central em fibras musculares
Frequente (79-30%)
100%prev.
Corpos de nemalina
Ocasional (29-5%)
100%prev.
Fraqueza muscular
Frequência: 4/4
100%prev.
Hipotonia neonatal
Frequência: 4/4
100%prev.
Fibras musculares esqueléticas com núcleo central
Frequência: 2/2
100%prev.
Habilidade atrasada de andar
Frequência: 4/4
43sintomas
Muito frequente (11)
Frequente (16)
Ocasional (6)
Muito raro (5)
Sem dados (5)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 43 características clínicas mais associadas, ordenadas por frequência.

Regiões de núcleo central em fibras muscularesCentral core regions in muscle fibers
Frequente (79-30%)100%
Corpos de nemalinaNemaline bodies
Ocasional (29-5%)100%
Fraqueza muscularMuscle weakness
Frequência: 4/4100%
Hipotonia neonatalNeonatal hypotonia
Frequência: 4/4100%
Fibras musculares esqueléticas com núcleo centralCentrally nucleated skeletal muscle fibers
Frequência: 2/2100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico472PubMed
Últimos 10 anos102publicações
Pico202013 papers
Linha do tempo
2025Hoje · 2026🧪 1990Primeiro ensaio clínico📈 2020Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

RYR1Ryanodine receptor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules (PubMed:11741831, PubMed:16163667, PubMed:18268335, PubMed:18650434, PubMed:26115329). Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm (PubMed:18268335). Can also mediate the release of Ca(2+)

LOCALIZAÇÃO

Sarcoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Ion homeostasisStimuli-sensing channels
MECANISMO DE DOENÇA

Malignant hyperthermia 1

Autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the 'in vitro' contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively).

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
423.5 TPM
Cerebelo
21.3 TPM
Cérebro - Hemisfério cerebelar
15.4 TPM
Hipotálamo
13.6 TPM
Testículo
8.7 TPM
OUTRAS DOENÇAS (13)
King-Denborough syndromecongenital multicore myopathy with external ophthalmoplegiacentral core myopathymalignant hyperthermia, susceptibility to, 1
HGNC:10483UniProt:P21817

Variantes genéticas (ClinVar)

6,385 variantes patogênicas registradas no ClinVar.

🧬 RYR1: NM_000540.3(RYR1):c.1456del (p.Val486fs) ()
🧬 RYR1: NM_000540.3(RYR1):c.14555A>C (p.Tyr4852Ser) ()
🧬 RYR1: NM_000540.3(RYR1):c.7061T>C (p.Val2354Ala) ()
🧬 RYR1: NM_000540.3(RYR1):c.528G>C (p.Glu176Asp) ()
🧬 RYR1: NM_000540.3(RYR1):c.5011_5048del (p.Ala1671fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3 variantes classificadas pelo ClinVar.

1
2
Patogênica (33.3%)
VUS (66.7%)
VARIANTES MAIS SIGNIFICATIVAS
RYR1: NM_000540.3(RYR1):c.10501dup (p.Asp3501fs) [Conflicting classifications of pathogenicity]
RYR1: NM_000540.3(RYR1):c.6891+3G>T [Uncertain significance]
RYR1: NM_000540.3(RYR1):c.131G>A (p.Arg44His) [Uncertain significance]

Vias biológicas (Reactome)

2 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença do núcleo central

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

5 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
102 papers (10 anos)
#1

Molecular Insights into Central Core Disease: Proteomic Signatures and Potential Therapeutic Biomarkers in RYR1 I4895T Mice.

International journal of molecular sciences2025 Nov 26

Central Core Disease (CCD) is a congenital myopathy predominantly caused by mutations in the gene encoding ryanodine receptor type-1 (RYR1), the intracellular Ca2+ release channel embedded in the skeletal muscle sarcoplasmic reticulum membrane. The I4898T mutation represents one of the most common RYR1 mutations associated with CCD. Unfortunately, there are no approved therapies for CCD or for other myopathies caused by mutations in this gene. This study aims to perform a top-down differential proteomic analysis on soleus muscle samples from wild-type mice (WT) and heterozygous knock-in mice carrying the I4895T (IT) mutation in RyR1, to investigate the pathogenic mechanisms and molecular pathways involved in this myopathy and to shed light on new potential biomarkers useful for future therapies. Proteomic analysis revealed 50 dysregulated protein species, and multivariate analysis showed that IT mice exhibit a distinct proteomic signature compared to WT mice, characterized by alterations in proteins associated with contractile and structural dysfunction, metabolism, and stress response. In particular, a significant increase in myosin fragments was observed in IT mice, likely due to muscle breakdown. In contrast, myotilin was downregulated, suggesting a weakening of the muscle cytoskeletal structure. There was a notable downregulation of proteins involved in glycolysis and the TCA cycle; conversely, there was an increase in proteins related to anaerobic glycolysis, suggesting a shift from aerobic to anaerobic glycolysis. Furthermore, proteins involved in fatty acid beta-oxidation and oxidative phosphorylation were also found to be upregulated in IT mice, indicating an attempt by the muscle to maximize energy production. Finally, we found a significant decrease in PGC1α, which could serve as potential therapy target and biomarker in CCD.

#2

Ca2+, ROS, IL-6, and p38 MAPK signaling loops underlying alterations in myotube formation induced by a severe MH/CCD mutation in RyR1.

American journal of physiology. Cell physiology2025 Dec 01

Mutations in the gene encoding the skeletal muscle ryanodine receptor (RyR1) can result in muscle diseases, termed RyR1-related myopathies (RyR1-RM). Examples include malignant hyperthermia (MH), central core disease (CCD), and centronuclear myopathy (CNM). The muscles involved often have more (and mispositioned) nuclei than normal. A subset of the corresponding mutant proteins shows an overactive or leaky sarcoplasmic reticulum (SR) channel behavior that depletes the SR Ca2+ content and increases the level of cytosolic Ca2+. In addition, two remarkable effects of these RyR1 variants have been reported in cultured myogenic cells: enhanced expression of interleukin-6 (IL-6) and stimulation of myoblast fusion (myonuclei accretion). Here, we have investigated whether the latter effect is due to a possible IL-6-dependent autocrine loop. Toward this goal, we analyzed the impact of the overactive Y523S mutant compared with the wild-type RyR1 after expression in C2C12 cells. The results show that this mutation indeed drastically promotes myoblast fusion up to ∼300%. Moreover, this action depends on the sequential activation of SR Ca2+ release, store-operated Ca2+ channels, reactive oxygen species (ROS, cytosolic and mitochondrial), calpain, and calcineurin. In addition, a neutralizing antibody directed against IL-6 and a p38 inhibitor completely suppressed the stimulation of myoblast fusion. Furthermore, in RyR1-expressing cells, myotube formation was promoted by either exogenous IL-6 or conditioned medium obtained from the Y523S-expressing cells. These findings suggest an autocrine mechanism involving the interplay between Ca2+, ROS, IL-6, and p38 signaling pathways in controlling myonuclei density, which could be essential to explain the pathogenesis of RyR1-RM.NEW & NOTEWORTHY Overactive RyR1 mutant proteins are associated with muscle disease; interestingly, they increase the number of myonuclei when expressed in C2C12 cells. We discovered that this alteration depends on a Ca2+/ROS loop, which recruits calpain and calcineurin to stimulate the production of IL-6 and the subsequent autocrine activation of p38. Thus, disease-causing RyR1 mutations require an IL-6 autocrine system to alter myonuclear density. This novel mechanism could be critical to understanding the pathogenesis of congenital myopathies.

#3

Two journeys, one diagnosis: exploring the clinical outcomes of twins with congenital myopathy.

BMC neurology2025 Oct 29

Mutations in the RYR1 gene, responsible for encoding the skeletal muscle calcium release channel, are linked to conditions such as malignant hyperthermia and central core disease. These mutations can severely affect calcium handling and excitation-contraction coupling, leading to different clinical manifestations including muscle fiber abnormalities. We present two siblings diagnosed with congenital myopathy due to a homozygous variant c.14,928 C > G (p.Phe4976Leu) in the RYR1 gene, inherited in an autosomal recessive pattern. Both twins, born prematurely via cesarean section, exhibited hypotonia and arthrogryposis. Clinical exome sequencing confirmed the RYR1 mutation, and an antioxidant supplement, idebenone, was introduced. Despite sharing the same variant, the twins presented discordant clinical phenotypes with varying degrees of muscle impairment and other complications. This case highlights the critical role of epigenetic in modulating disease expression, suggesting personalized therapeutic strategies are paramount even in siblings sharing the same homozygous variant.

#4

A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps.

European journal of neurology2025 Jan

Pathogenic variants in the RYR1 gene have been associated with a variety of conditions, ranging from congenital myopathy to adult manifestations. Our aim was to characterize the p.Leu2286Val variant in 17 Basque patients, to accurately determine its correlation with clinical features and to explore the possible founder effect of the variant. Families harbouring the p.Leu2286 RYR1 variant underwent a detailed clinical evaluation, including muscle magnetic resonance imaging, electromyography and muscle biopsy. Haplotypes were analysed in available patients and their relatives. Individuals carrying the p.Leu2286Val shared a common haplotype, suggesting a founder event in the Basque Country population. The most prevalent features were exertional myalgia, high creatine kinase (CK) levels, cramps and muscle hypertrophy. None of the patients carrying only the p.Leu2286Val showed progression to severe muscle weakness and muscle magnetic resonance imaging showed a heterogeneous muscle involvement. Muscle biopsy revealed non-specific findings in two patients and features associated with central core disease in one patient carrying only the p.Leu2286Val and two patients harbouring an additional RYR1 variant. Three individuals carrying an in trans RYR1 variant presented with an earlier onset and more severe phenotype. Here, it is shown that the dominantly inherited p.Leu2286Val RYR1 founder variant is associated with a milder phenotype of exercise intolerance, myalgia and hyperCKemia.

#5

RYR1-Related Myopathies Involve More than Calcium Dysregulation: Insights from Transcriptomic Profiling.

Biomolecules2025 Nov 14

Ryanodine receptor 1-related myopathies (RYR1-RM) are caused by RYR1 gene variants and comprise a wide spectrum of histopathological manifestations. Here, we focus on patients carrying RYR1 variants and muscle histopathology consistent with central core disease (CCD) or multi-minicore disease (MmD). RNA-sequencing analyses of skeletal muscle biopsies obtained from both CCD and MmD patients and from healthy controls were performed to better understand the molecular pathways activated by RYR1 variants. Our analyses revealed that, beyond the well-established role of RYR1 in calcium homeostasis, broader cellular pathways are implicated. In CCD, differentially expressed genes were enriched for pathways related to oxidative stress response, SMAD signalling, and apoptosis, consistent with the role of intracellular calcium dysregulation in promoting mitochondrial dysfunction and cell death. In contrast, MmD patients exhibited enrichment of pathways related to immune activation. This was corroborated by the upregulation of GTPase-regulating genes and the down-regulation of transcriptional repressors such as ZFP36 and ATN1. When considering all RYR1-RM patients collectively, Wnt signalling, immune-related pathways, and oxidative phosphorylation emerged as shared enriched pathways, indicating possible convergent mechanisms across histopathological phenotypes. Our study suggests that complex gene regulation driven by RYR1 variants may be a unifying feature in CCD and MmD, offering new insight into potential therapeutic targets.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC192 artigos no totalmostrando 100

2025

Molecular Insights into Central Core Disease: Proteomic Signatures and Potential Therapeutic Biomarkers in RYR1 I4895T Mice.

International journal of molecular sciences
2025

RYR1-Related Myopathies Involve More than Calcium Dysregulation: Insights from Transcriptomic Profiling.

Biomolecules
2025

Muscle imaging of patients with RYR1-related myopathies and its significance to clinical features.

Neuromuscular disorders : NMD
2025

Ca2+, ROS, IL-6, and p38 MAPK signaling loops underlying alterations in myotube formation induced by a severe MH/CCD mutation in RyR1.

American journal of physiology. Cell physiology
2025

Therapeutic Challenges in Managing Triple-Negative Breast Cancer in a Patient With Central Core Disease.

Cureus
2025

Two journeys, one diagnosis: exploring the clinical outcomes of twins with congenital myopathy.

BMC neurology
2025

Limited pre-clinical relevance of the heterozygous RYR1-I4895T/+ mouse model due to its mild phenotype.

Journal of neuromuscular diseases
2025

A systematic review on motor outcome measures in congenital myopathy.

Neuromuscular disorders : NMD
2025

Perioperative management of cesarean section in pregnant women complicated by central core disease: A case report and literature review.

Medicine
2025

Report of joint hypermobility in malignant hyperthermia susceptible patients: Observational study with a case-control descriptive design.

Heliyon
2025

A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps.

European journal of neurology
2025

Dantrolene inhibition of ryanodine receptor 1 carrying the severe malignant hyperthermia mutation Y522S visualized by cryo-EM.

Structure (London, England : 1993)
2024

Functional benefit of CRISPR-Cas9-induced allele deletion for RYR1 dominant mutation.

Molecular therapy. Nucleic acids
2024

[Clinical features and genetic analysis of a child with Central core disease due to compound heterozygous variants of RYR1 gene].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2024

Perioperative management of bronchoscopy in a child patient with central core disease: A case report and literature review.

International journal of surgery case reports
2024

Generation of two iPSC lines from patients with inherited central core disease and concurrent malignant hyperthermia caused by dominant missense variants in the RYR1 gene.

Stem cell research
2024

Generation of two iPSC lines from adult central core disease patients with dominant missense variants in the RYR1 gene.

Stem cell research
2024

Anesthetic Management of a Patient With Central Core Disease Undergoing Thoracoscopic Lung Resection: The Importance of Neuromuscular Monitoring at the Masseter Muscle.

Cureus
2024

Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial.

EClinicalMedicine
2023

A case report of central core disease with repeated foaming at the mouth as the initial symptom.

Medicine
2023

Generation of two induced pluripotent stem cell lines from a 33-year-old central core disease patient with a heterozygous dominant c.14145_14156delCTACTGGGACA (p.Asn4715_Asp4718del) deletion in the RYR1 gene.

Stem cell research
2023

A brief history of the congenital myopathies - the myopathological perspective.

Neuromuscular disorders : NMD
2023

Pancreatitis in RYR1-related disorders.

Neuromuscular disorders : NMD
2023

Rhabdomyosarcoma Associated with Core Myopathy/Malignant Hyperthermia: Combined Effect of Germline Variants in RYR1 and ASPSCR1 May Play a Role.

Genes
2023

A novel RYR1 variant in an infant with a unique fetal presentation of central core disease.

American journal of medical genetics. Part A
2023

Drug development for the treatment of RyR1-related skeletal muscle diseases.

Current opinion in pharmacology
2022

Loss-of-rescue of Ryr1I4895T-related pathology by the genetic inhibition of the ER stress response mediator CHOP.

Scientific reports
2022

Pharmacokinetics of Dantrolene in the Plasma Exchange Treatment of Malignant Hyperthermia in a 14-Year-Old Chinese Boy: A Case Report and Literature Review.

Frontiers in medicine
2022

Molecular mechanism of the severe MH/CCD mutation Y522S in skeletal ryanodine receptor (RyR1) by cryo-EM.

Proceedings of the National Academy of Sciences of the United States of America
2022

[Clinical characteristics and genetic analysis of a pedigree affected with neonatal central core disease].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2022

Structural Insight Into Ryanodine Receptor Channelopathies.

Frontiers in pharmacology
2023

A review of major causative genes in congenital myopathies.

Journal of human genetics
2022

Central Core Disease: Facial Weakness Differentiating Biallelic from Monoallelic Forms.

Genes
2022

Congenital myopathies: The current status.

Indian journal of pathology &amp; microbiology
2022

Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study.

Acta neuropathologica communications
2022

Variant landscape of the RYR1 gene based on whole genome sequencing of the Singaporean population.

Scientific reports
2022

Mutation in RyR2-FKBP Binding site alters Ca2+ signaling modestly but increases "arrhythmogenesis" in human stem cells derived cardiomyocytes.

Cell calcium
2021

A review of core myopathy: central core disease, multiminicore disease, dusty core disease, and core-rod myopathy.

Neuromuscular disorders : NMD
2021

A recurrent RYR1 mutation associated with early-onset hypotonia and benign disease course.

Acta neuropathologica communications
2021

The mitochondrial calcium homeostasis orchestra plays its symphony: Skeletal muscle is the guest of honor.

International review of cell and molecular biology
2023

Marked Facial Weakness, Ptosis, and Hanging Jaw: A Case with RYR1 -Related Congenital Centronuclear Myopathy.

Journal of pediatric genetics
2021

Asymmetrical anterior thigh muscle atrophy as an atypical presentation of RYR1-core myopathy.

Neuromuscular disorders : NMD
2021

Altered Ca2+ Handling and Oxidative Stress Underlie Mitochondrial Damage and Skeletal Muscle Dysfunction in Aging and Disease.

Metabolites
2021

A case of dermatomyositis in a patient with central core disease: unusual association with autoimmunity and genetic muscle disease.

Pediatric rheumatology online journal
2021

Congenital Myopathies: A Clinicopathological Study of 10 Cases in a Tertiary Care Hospital of North India.

Journal of pediatric neurosciences
2020

Dominant or recessive mutations in the RYR1 gene causing central core myopathy in Brazilian patients.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2020

Core myopathies - a short review.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2021

Novel ACTA1 mutation causes late-presenting nemaline myopathy with unusual dark cores.

Neuromuscular disorders : NMD
2020

Evaluation of the Core Formation Process in Congenital Neuromuscular Disease With Uniform Type 1 Fiber and Central Core Disease.

Journal of neuropathology and experimental neurology
2020

In vivo RyR1 reduction in muscle triggers a core-like myopathy.

Acta neuropathologica communications
2020

New Compound Heterozygous Splice Site Mutations of the Skeletal Muscle Ryanodine Receptor (RYR1) Gene Manifest Fetal Akinesia: A Linkage with Congenital Myopathies.

Molecular syndromology
2020

Management of pregnancy complicated by central core disease.

International journal of obstetric anesthesia
2020

Thirty years of translational research in Mobility Medicine: Collection of abstracts of the 2020 Padua Muscle Days.

European journal of translational myology
2020

Bi-allelic expression of the RyR1 p.A4329D mutation decreases muscle strength in slow-twitch muscles in mice.

The Journal of biological chemistry
2020

Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Orphanet journal of rare diseases
2020

Clinical Observation: Effect of a Second Transpositioned Variant in a Family with Autosomal Dominant Ryanodine Receptor-1-Related Disease.

Journal of pediatric genetics
2020

Intracellular calcium leak as a therapeutic target for RYR1-related myopathies.

Acta neuropathologica
2020

Single Amino Acid Changes in the Ryanodine Receptor in the Human Population Have Effects In Vivo on Caenorhabditis elegans Neuro-Muscular Function.

Frontiers in genetics
2020

Impact of scoliosis surgery on pulmonary function in patients with muscular dystrophies and spinal muscular atrophy.

Pediatric pulmonology
2019

Cored in the act: the use of models to understand core myopathies.

Disease models &amp; mechanisms
2019

Significance of Asymptomatic Hyper Creatine-Kinase Emia.

Journal of clinical neuromuscular disease
2019

Functional Electrical Stimulation: A Possible Strategy to Improve Muscle Function in Central Core Disease?

Frontiers in neurology
2019

A central core disease mutation in the Ca2+-binding site of skeletal muscle ryanodine receptor impairs single-channel regulation.

American journal of physiology. Cell physiology
2019

RYR1 Sequence Variants in Myopathies: Expression and Functional Studies in Two Families.

BioMed research international
2019

Therapeutic Aspects in Congenital Myopathies.

Seminars in pediatric neurology
2019

Pregnancy and Delivery in Women With Congenital Myopathies.

Seminars in pediatric neurology
2019

Severe Neonatal RYR1 Myopathy With Pathological Features of Congenital Muscular Dystrophy.

Journal of neuropathology and experimental neurology
2019

Homozygous/compound heterozygote RYR1 gene variants: Expanding the clinical spectrum.

American journal of medical genetics. Part A
2019

'Dusty core disease' (DuCD): expanding morphological spectrum of RYR1 recessive myopathies.

Acta neuropathologica communications
2018

Ryanodine Receptor 1-Related Myopathies: Diagnostic and Therapeutic Approaches.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2018

Disturbed Ca2+ Homeostasis in Muscle-Wasting Disorders.

Advances in experimental medicine and biology
2018

Calcium Channelopathies: Structural Insights into Disorders of the Muscle Excitation-Contraction Complex.

Annual review of genetics
2018

Characterization of congenital myopathies at a Korean neuromuscular center.

Muscle &amp; nerve
2018

Clinical and Pathologic Findings of Korean Patients with RYR1-Related Congenital Myopathy.

Journal of clinical neurology (Seoul, Korea)
2018

Parental mosaicism in RYR1-related Central Core Disease.

Neuromuscular disorders : NMD
2018

Central core disease with scoliosis for congenital hip dislocation surgery: An anaesthetic demur.

Indian journal of anaesthesia
2018

Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction.

Nature reviews. Neurology
2017

Antioxidant Treatment Reduces Formation of Structural Cores and Improves Muscle Function in RYR1Y522S/WT Mice.

Oxidative medicine and cellular longevity
2017

Common and variable clinical, histological, and imaging findings of recessive RYR1-related centronuclear myopathy patients.

Neuromuscular disorders : NMD
2017

Reduced threshold for store overload-induced Ca2+ release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease.

The Biochemical journal
2017

Ion-pulling simulations provide insights into the mechanisms of channel opening of the skeletal muscle ryanodine receptor.

The Journal of biological chemistry
2017

Whole exome sequencing of a patient with suspected mitochondrial myopathy reveals novel compound heterozygous variants in RYR1.

Molecular genetics &amp; genomic medicine
2017

Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.

Journal of neuromuscular diseases
2017

Young onset Parkinsonism in a patient with familial central core disease.

Neurology India
2015

Functional Characterization of a Central Core Disease RyR1 Mutation (p.Y4864H) Associated with Quantitative Defect in RyR1 Protein.

Journal of neuromuscular diseases
2016

Malignant hyperthermia-associated mutations in the S2-S3 cytoplasmic loop of type 1 ryanodine receptor calcium channel impair calcium-dependent inactivation.

American journal of physiology. Cell physiology
2016

Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.

Human mutation
2016

Congenital myopathies: not only a paediatric topic.

Current opinion in neurology
2017

Current and future therapeutic approaches to the congenital myopathies.

Seminars in cell &amp; developmental biology
2016

[Anesthetic Management of a Patient with Central Core Disease for Scoliosis Surgery].

Masui. The Japanese journal of anesthesiology
2016

Coexistence of central nucleus, cores, and rods: Diagnostic relevance.

Annals of Indian Academy of Neurology
2016

Next generation sequencing reveals ryanodine receptor 1 mutations in a Chinese central core disease cohort.

Muscle &amp; nerve
2016

Bilateral congenital lumbar hernias in a patient with central core disease--A case report.

Neuromuscular disorders : NMD
2015

Novel pathogenic variants and genes for myopathies identified by whole exome sequencing.

Molecular genetics &amp; genomic medicine
2015

Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.

PloS one
2015

Oxidative stress, mitochondrial damage, and cores in muscle from calsequestrin-1 knockout mice.

Skeletal muscle
2015

A novel large deletion in the RYR1 gene in a Belgian family with late-onset and recessive core myopathy.

Neuromuscular disorders : NMD
2015

Two families with MYH7 distal myopathy associated with cardiomyopathy and core formations.

Journal of clinical neuromuscular disease
2015

Mild Clinical Features and Histopathologically Atypical Cores in Two Korean Families with Central Core Disease Harboring RYR1 Mutations at the C-Terminal Region.

Journal of clinical neurology (Seoul, Korea)
2015

Potassium dependent rescue of a myopathy with core-like structures in mouse.

eLife
Ver todos os 192 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença do núcleo central.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença do núcleo central

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Molecular Insights into Central Core Disease: Proteomic Signatures and Potential Therapeutic Biomarkers in RYR1 I4895T Mice.
    International journal of molecular sciences· 2025· PMID 41373610mais citado
  2. Ca2+, ROS, IL-6, and p38 MAPK signaling loops underlying alterations in myotube formation induced by a severe MH/CCD mutation in RyR1.
    American journal of physiology. Cell physiology· 2025· PMID 41212187mais citado
  3. Two journeys, one diagnosis: exploring the clinical outcomes of twins with congenital&#xa0;myopathy.
    BMC neurology· 2025· PMID 41162937mais citado
  4. A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps.
    European journal of neurology· 2025· PMID 39742415mais citado
  5. RYR1-Related Myopathies Involve More than Calcium Dysregulation: Insights from Transcriptomic Profiling.
    Biomolecules· 2025· PMID 41301517mais citado
  6. Muscle imaging of patients with RYR1-related myopathies and its significance to clinical features.
    Neuromuscul Disord· 2025· PMID 41270518recente
  7. Therapeutic Challenges in Managing Triple-Negative Breast Cancer in a Patient With Central Core Disease.
    Cureus· 2025· PMID 41209931recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:597(Orphanet)
  2. OMIM OMIM:117000(OMIM)
  3. MONDO:0007294(MONDO)
  4. GARD:6014(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q638975(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença do núcleo central
Compêndio · Raras BR

Doença do núcleo central

ORPHA:597 · MONDO:0007294
Prevalência
1-9 / 1 000 000
Herança
Autosomal dominant
CID-10
G71.2 · Miopatias congênitas
CID-11
Ensaios
3 ativos
Início
Childhood
Prevalência
0.4 (United Kingdom)
MedGen
UMLS
C0751951
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades